Dr. Bhuvan Chugh is a Medical Oncologist and clinical leader known for clear, evidence-based treatment planning and for guiding patients confidently through complex cancer decisions. His primary areas of clinical focus are Breast and Thoracic cancers. Dr. Chugh practices precision-led cancer care, using genomic testing when it can meaningfully change treatment direction. His work includes innovative applications of advanced molecular diagnostics in challenging scenarios, including CSF-based genomic sequencing–guided management in EGFR-mutant lung cancer with leptomeningeal disease (presented at ALKlinic 2025; published in the Journal of Liquid Biopsy). He served as Past Convenor of the Max Healthcare–Foundation Medicine India Molecular Tumor Board and is known for contributing to complex multidisciplinary decision-making across multiple disease-site tumor boards. He previously served as Principal Consultant, Medical Oncology at Max Super Specialty Hospital (Saket and Gurugram) and as Clinical Lead, Medical Oncology at Max Hospital, Gurugram, where he built and matured medical oncology services from a nascent day-care setup into a comprehensive, protocol-driven program with strong multidisciplinary coordination. He earlier worked as a consultant at Medanta, The Medicity (Gurugram) in the Department of Medical Oncology & Hematology after completing his DNB (Medical Oncology), gaining extensive experience managing a wide spectrum of complex cancers in a high-volume tertiary-care setting. He has presented his work at ASCO and ESMO through multiple abstracts and posters, and is joining Apollo Hospitals (Delhi–NCR network) as Lead Consultant, Medical Oncology, focused on patient-first care that blends evidence-based protocols, multidisciplinary expertise, and precision diagnostics—so patients and families can make decisions with clarity and confidence. Known for simplifying complex medical choices into practical next steps, he has also shared this approach as a TEDx speaker.
Clinical focus: Breast cancer, Thoracic oncology Also treats (selected cases): Head & Neck cancers, Sarcomas
Read More
Ask your query
Special interest
Breast, Thoracic, Head & Neck cancers, Sarcomas
Precision Oncology Leader: CSF genomic sequencing–guided treatment in lung cancer (landmark publication).
Treatment of complex breast cancer cases, including post initial lines of therapy, those with with leptomeningeal disease and those with co-morbidities
Built and led a comprehensive oncology program at Max Gurugram
Advacned Certification in Molecular Oncology (Sidney Kimmel/Thomas Jefferson)
Memberships
American Society of Clinical Oncology (ASCO)
European Society of Medical Oncology (ESMO)
Internation Association for the Study of Lung Cancer (IASLC)
Indian Society of Medical & Pediatric Oncology (ISMPO)
Indian Medical Association (IMA) Oncology Forum
Awards & Achievements
Clinical advisor to genomics and precision diagnostics initiatives in India
Multiple ASCO/ESMO presentations and indexed publications (first author & co-author)
TEDx Speaker
IMA (NDB) Award of Excellence in Oncology (2024)
BusinessWorld (BW) 40 Under 40 Award recipient
Member ISMPO–Illumina Precision Oncology Working Group (2024)
Presented CSF genomic sequencing–guided management of leptomeningeal disease in EGFR-mutant NSCLC (ALKlinic 2025, Taipei, Taiwan)
Invited Speaker: SCCHN Preceptorship, Centre Antoine Lacassagne, Nice, France (Nov 2025)
ESMO Asia 2024 – Best Poster Award (co-author)
Contributor to breast & lung cancer consensus and guideline-driven practice
Former Convenor, Max Healthcare–Foundation Medicine Molecular Tumor Board
Advanced Certification in Molecular Oncology (Sidney Kimmel/Thomas Jefferson)
Research & Publications
01
Presentations in International conferences
02
OncoTwin Insights: A Clinicogenomic Similarity-Based Decision Support System for Precision Therapy in Lung Cancer. (ID 2248). Poster Presentation – ESMO Asia, December 2025, First Author.
03
Comprehensive germline sequencing and MLPA analysis in breast cancer patients: 4 years of experience from an Indian cancer institute. (First Author, Accepted as Online Only presentation in ASCO Annual Meeting 2025)
04
Driving precision oncology in lung cancer: Patient stratification through comprehensive genomic profiling. (Co-Author, Accepted as Poster in ASCO Annual Meeting 2025)
05
Landscape of Metastatic Colorectal Cancer (CRC) using Comprehensive circulating tumor DNA (ctDNA) Next Generation Sequencing (NGS) in India: Expanding Beyond RAS and RAF. (Co-Author, Accepted Poster in ASCO GI 2025)
06
Genomic mutational profile of breast cancer patients from India through comprehensive next-generation sequencing analysis of circulating tumor DNA. ESMO 2024 – Best Poster Award
07
Circulating tumor cells in clinically stable patients demonstrates the conundrum of recurrence with cellular residual disease. ASCO Annual Meeting 2024
08
Differences in the Clinicopathological Feature, Prognostic Features and Treatment Outcomes between Molecular Subtypes Among Indian Cohort with Diffuse Large B- Cell Lymphoma - a Single Centre Experience; Blood 134 (Supplement_1):5350-5350.; November 2019
09
A Prospective Observational Study of Clinico-Pathological Features, Prognostic Factors and Treatment Response to Primary Therapy in Multiple Myeloma at a Tertiary Care Centre; Blood 134 (Supplement_1):5559-5559; November 2019
10
Abstract Publication in BTG2018, 9th International Hematologic Malignancies Conference held in Seoul, South Korea from March 29-31, 2018
11
In National Conferences:
12
A Prospective Study of Clinico-pathological features, Prognostic factors, and Response rates in Advanced Non-small Cell Lung Cancer Patients Eligible for Chemotherapy - A Single Centre Experience at 37th ICON New Delhi. 2017
13
Systemic Therapies in Hepatocellular Carcinoma (In Publication)
14
Chapter titled ‘Key Takeaways from International Guidelines on Gastric Cancer’ in the book ‘Gastric Cancer’ by Springer Healthcare Education
15
Chapter titled ‘Biomarkers in Cardiac Disease’ in the book ‘Progress in Medicine’ Volume XXIX year 2015 by Association of Physicians of India-Indian College of Physicians (API-ICP)
16
Malik PS, Baral R, Chugh B, Dawoud E, Forde P, Ghosn M, et al. Excellence in oncology care (EIOC) consensus guidelines on integrating immunotherapy (IO) in resectable non-small cell lung cancer (NSCLC) for the Middle East and Indian subcontinent. Cancer Res Stat Treat. 2025 Oct-Dec;8(4):298-303. doi:10.4103/crst.crst_15_25.
17
Chugh B, et al. Crossing barriers with CSF-based sequencing for leptomeningeal disease in EGFR mutant NSCLC. J Liq Biopsy. 2025;10:100332.
18
Investigating the genomic landscape of sarcoma in India: Discoveries from a retrospective observational approach in Cancer Research, Statistics and Treatment, August 2025 (contributing author)
19
Rastogi, R. et al. (2024) ‘Von Meyerberg complexes: An underrecognized predisposing factor for focal nodular hyperplasia–like lesions’, Indian Journal of Radiology and Imaging [Preprint]. doi:10.1055/s-0044-1801266.
20
Molecular insights from comprehensive genomic profiling data in advanced metastatic colorectal cancer in South Asian population: A retrospective observational study; Cancer Research, Statistics and Treatment 7(2):p 193-205, Apr–Jun 2024
21
Clinicohematologic and cytogenetic profile in a rare case of pure erythroid leukaemia; Annals of Hematology 98(3); March 2019
22
Myelodysplastic syndromes: Where do we stand? Asian Journal of Oncology. April 2016
23
Outcomes of patients presenting with acute coronary syndrome with vitamin D deficiency. Indian Heart Journal. November 2014
24
DOTS expansion under the umbrella of IMA: Success story continues along with early teething difficulties. Journal of the Indian Medical Association. July 2008
25
Evaluation of circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTC) for detecting Minimal Residual Disease in Early-Stage Triple-Negative Breast Cancer Post-Neoadjuvant Chemotherapy. REACT Study
26
A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as First-line Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC With PD-L1 TPS greater than/equal to 50% at Max Super Speciality Hospital (Site Verification Ongoing)
27
A Registry To Collect Characteristics And Outcomes From Patients With Solid Tumors Profiled With A Next-Generation Sequencing Test (WAYFIND-R).
28
A Prospective, Multicenter, Non-Interventional, Observational, Real-World Study to Evaluate the Safety, Adherence to Therapy, and Effectiveness of a T-DM1 Antibody Drug Conjugate Biosimilar in Indian Patients with HER2-Positive Early Breast Cancer
29
Ongoing studies: (As PI) PRISM-AI: PRISM-AI: Patient-reported musculoskeletal, menopausal, and urogenital symptoms and their psychological impact, reporting patterns, and treatment adherence among women with hormone receptor–positive breast cancer on adjuvant aromatase inhibitors — a cross-sectional observational study
30
Thesis Guide/Co-Guide: Role of next generation sequencing (NGS)/comprehensive genomic profiling (CGP) in cancer patients – evaluating impact on clinical outcomes in real world settings. (2024-25)
Best Hospital Near me Chennai